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In the current article we summarize the 15-year experience of the Spanish Cell Therapy Network (TerCel), a
successful collaborative public initiative funded by the Spanish government for the support of nationwide
translational research in this important area. Thirty-two research groups organized in three programs
devoted to cardiovascular, neurodegenerative and immune-inflammatory diseases, respectively, currently
form the network. Each program has three working packages focused on basic science, pre-clinical studies
and clinical application. TerCel has contributed during this period to boost the translational research in cell
therapy in Spain, setting up a network of Good Manufacturing Practicecertified cell manufacturing facili-
ties and increasing the number of translational research projects, publications, patents and clinical trials of
the participating groups, especially those in collaboration. TerCel pays particular attention to the public-pri-
vate collaboration, which, for instance, has led to the development of the first allogeneic cell therapy product
approved by the European Medicines Agency, Darvadstrocel. The current collaborative work is focused on
the development of multicenter phase 2 and 3 trials that could translate these therapies to clinical practice
for the benefit of patients.
© 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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e Therapy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.Introduction
In the last two decades, the emerging field of regenerative medicine
and cell therapy has drawn the attention of many basic researchers,clinicians and also the general population. The therapeutic potential of
cells for a number of degenerative and/or severe diseases that currently
lack a definitive treatment has promptedmany private and public initia-
tives worldwide, especially in the USA and Asian countries [1,2].
The European Union (EU) has the advantage of a common
regulatory framework and the existence of the hospital exemption
rule for the administration of advanced therapies medicinal
products (ATMPs). However, this background has fostered single-
institutionbased experiences and small phase 1 and 2 clinical trials
Table 1
ATMPs in Europe that obtained MA.
Product Disease Holder of MA Y
ChondroCelect Cartilage disease Tigenix 2009a
Glybera Type 1 hyperlipoproteinemia UniQure 2012a
MACI Cartilage disease Aastrom 2013a
Provenge Prostate cancer Dendreon 2013a
Holoclar Corneal disease Chiesi 2015
Imlygic Melanoma Amgen 2015
Strimvelis Severe combined
inmmunodeficiency
GSK 2016
Zalmoxis Hematopoietic transplantation MolMed 2016
Spherox Condral lesions CO.DON 2017
Alofisel Perianal fistula in Crohn’s disease Takeda 2018
Kymriah Acute lymphoid leukemia and
diffuse large B-cell lymphoma
Novartis 2018
Yescarta Diffuse large B-cell lymphoma and
primary mediastinal B-cell
lymphoma
Kite 2018
EMA, European Medicines Agency, MA, marketing authorization.
a MAwas withdrawn or suspended by the EMA afterward due to different reasons.
Fig. 1. Scientific strategy of TerCel.
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als, at least at the national level. It is clear that collaborative efforts in
this new area of translational research will be needed to achieve the
global aim of transferring these treatments from the bench to the
bedside within the shortest possible time [3,4]. But, as indicated,
there are only a small number of published phase 3 trials and very
few cell therapy products have reached the final process of authoriza-
tion by the regulators. As of June 2018, there are only three cell prod-
ucts of 12 ATMPs approved for marketing in Europe (Table 1). It
should be noted that approval of ATMP in the EU has a number of
inherent difficulties, based on quality issues and the evaluation of
post-marketing risk management [5].
In this article we summarize the 15-year experience of the Span-
ish Cell Therapy Network (TerCel), a successful collaborative public
initiative funded by the Instituto de Salud Carlos III (ISCIII), the
agency of the Spanish government for the support of nationwide
translational research in health sciences.
Description and Objectives of TerCel
TerCel was established in 2003 with the aim of promoting transla-
tional research in cell therapy bringing together both basic research
groups and clinical investigators with a common interest in this area.
At that time, they were very few experiences in Europe organized
through the National Health System research structures to coordinate
stem cell research and cellular therapy at the national level. Cur-
rently, there are structures similar to TerCel in other EU countries,
but each one with their own peculiarities based on the way the trans-
lational research has been established in that country. For example, in
France they have developed ECell France for Regenerative Medicine
(created in 2012), in Italy the Instituti di Ricovero e Cura a Carattere
Scientifico (IRCCS) established a number of structures for cell produc-
tion and regenerative medicine research starting in 2000, the Medical
Research Council and other members of the UK Regenerative Medi-
cine Funders Forum had initiatives as the UK Regenerative Medicine
Platform (2013) or the Cell Therapy Catapult (2012) and The Nether-
lands Institute of Regenerative Medicine was established in 2009,
among others. It could be of interest, although it is out of the scope of
this article, to compare these platforms and structures not only in
terms of their characteristics but also of their outcomes.
The work of the TerCel consortium is organized in three main
healthcare areas: neurodegenerative diseases (NeuroCel program),
cardiovascular diseases (CardioCel program) and inflammatory,
immunologic and metabolic diseases (OshiCel program).
Research groups throughout the nation joined the network based
on an independent evaluation of their background in terms ofscientific output, competitive funding and areas of research. The pro-
grams are evaluated yearly and the scientific goals of the different
programs have been revisited in 2006, 2012 and 2016. TerCel started
with eight groups in 2003, and the number increased to 31 in 2006,
when new research groups were incorporated to the network based
on their expertise and ability to demonstrate competence and collab-
oration. Thereafter, the number of research groups has remained sta-
ble (between 31 and 33) to date, when 32 research groups are
included in the network (10 in CardioCel and 11 in both NeuroCel
and OshiCel). The total number of investigators is currently 351, with
31 directly sponsored by TerCel (11 PhD investigators, 12 graduate
students and 8 technicians).
There are six major strategic objectives of the network (Figure 1):
(i) to understand the mechanisms of repair and the regenerative prop-
erties of grafted and endogenous stem cells in tissues and organs, as
well as the role of the niche in regulating their function; (ii) to improve
stem cell functionality using new technologies such as cell engineering
or gene editing; (iii) to develop in vitro and in vivo disease models to
get safety and efficacy proof-of-concepts of these improved cell thera-
pies; (iv) to design and improve protocols for the isolation, manipula-
tion, expansion, storage and administration of cells for clinical use
under Good Manufacturing Practice (GMP) conditions; (v) to develop
collaborative multi-centric clinical trials to translate these therapies to
the clinical practice for the benefit of patients; and (vi) to design and
launch programs for rigorous dissemination of cell therapy knowledge
to society and fight against the fraud in this field.
Each program has a pipeline of three working packages (WPs)
aiming at specific objectives, deliverables and milestones to identify
cells and ATMPs of benefit in the treatment of human diseases. The
first WP of each program (WP1, or basic research WP) is devoted to
basic science and mostly includes in vitro analyses and understanding
of molecular mechanisms. WP2 (pre-clinical WPs) are focused on
pre-clinical studies of stem cell administration in animal models of
diseases of the corresponding area. WP3 (clinical WP) involves all the
stages of clinical application of cell products, from cell production
under GMP conditions to first-in-human clinical trials and advanced
collaborative clinical trials.
Management and Regulations of TerCel
TerCel belongs to a wide program of disease-oriented research net-
works (RETICs, Thematic Networks for Cooperative Research in Health)
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for scientific collaborative proposal applications by the programs of
every RETIC, which compete among them for financial support based
on a thorough external and independent evaluation.
TerCel is led and coordinated by a Managing Executive Committee
(MEC), which is composed of the network general coordinator, the
coordinator of each program (CardioCel, NeuroCel and OshiCel) as
well as the coordinators of each of the three (basic, pre-clinical and
clinical) WPs in each program. The tasks of MEC are as follows: (i) to
supervise the advances of the WPs and the accomplishment of deliv-
erables and milestones; (ii) to administer the funding received from
the ISCIII; (iii) to foster the scientific collaboration among research
groups; (iv) to discuss and design the scientific strategy; (v) to sup-
port the investigators in the preparation of scientific meetings and
scientific evaluations; (vi) to guarantee the adequate dissemination
of the results obtained both to the scientific community and to the
general public; and (vii) to establish scientific subcommittees to
address specific work priorities. In this last task, TerCel has created
several platforms and scientific subcommittees dedicated to the stan-
dardization of common protocols for basic research, to establish com-
mon animal models of diseases and uniform cell production protocols
under GMP conditions, to biobank pluripotent stem cell lines accord-
ing to the legislation, to facilitate the exchange of investigators
between research groups, to interact with the Spanish Medicines
Agency (which will be discussed later) and a very important one
focused on defining Good Clinical Practices in Cell Therapy. Indeed,
the Good Clinical Practices in Cell Therapy committee mission is to
clarify all the questions relevant to the patients who are offered cell
therapy treatments (there is a specific section in TerCel website
devoted to this [6]) and to identify illegal and fraudulent offers of cell
therapies in our area of influence. Regarding the GMP facilities
platform, each GMP facility shares with the others the academic
investigational medical product dossiers and its knowledge for Ter-
Cel-initiated collaborative clinical trials, but some of them are also
participating in industry-sponsored trials (where some of the
manufacturing process could be partially externalized) and in multi-
center European clinical trials (where they are either responsible for
the production or partners in this process). Funding of the
manufacturing by TerCel GMP facilities is always included in the proj-
ect budget for competitive national and EU grants.
TerCel has also an Internal Scientific Advisory Committee, formed
by all principal investigators of the research groups, and an External
Scientific Advisory Committee, integrated by four internationally
renowned experts in stem cell research and cell therapy. Finally, the
General Assembly, formed by all the investigators of the network,
meets once a year at the TerCel Annual Scientific Meeting. TerCel also
organizes an Annual Technical Workshop meeting open to the public,
where internal investigators and/or external experts discuss technol-
ogy-related advances around a specific topic selected by the MEC
each year (e.g., Chimeric Antigen Receptor T cells, organoids, biofabri-
cation). The goal is to analyze in detail emerging concepts in the field
and to raise public awareness on the advances at the forefront of cell
therapy research.
Main Achievements of TerCel
When analyzing the period 20132017, the number of publica-
tions of TerCel investigators add up to 1303, with a median of
260 manuscripts/year. Of the total number, 209 manuscripts were
the result of collaborative efforts of at least two groups of the net-
work, and 140 manuscripts had all authors exclusively from TerCel
groups. Therefore, collaboration between groups clearly fostered the
generation of synergies that resulted in more and higher impact
manuscripts. In this regard, the median impact factor (IF) of all manu-
scripts published by TerCel members in this period was 4.9, whereas
the IF of the articles published in collaboration between TerCelgroups was 6.5. Nevertheless, this is indeed still an IF value that
reflects the challenge of publishing translational research studies
with a low or medium number of patients in high-impact journals,
although the results may be important to further develop the field
(as it was during the early years of TerCel). It has to be acknowledged
that this fact has further negative consequences for getting additional
funding within universities or from other financing structures includ-
ing the European Commission.
In this same 20132017 period, the total number of competitive
research projects in which TerCel groups were involved was 487.
Seventy of them were the result of collaborations between groups of
the network, and in 61 only TerCel members were involved. The total
amount of financial support for these TerCel research projects in this
period was 144,169,242€.
The education program in this period has promoted and financed
a median of ten workshops a year related to ATMP therapies and a
median of three young investigator exchanges among TerCel groups.
The most important achievements of TerCel in its path from bench
to bedside have been the initiation of clinical trials involving ATMPs.
Between 2013 and 2017, TerCel groups initiated a total of 111 clinical
trials. Of them, 28 were developed in collaboration with TerCel
groups and in 22 only groups from the network participated. This is
quite an achievement because the public financial support for clinical
research in this period was very low due to the country’s economic
crisis [7]. Before the crisis, Spain was the leading European country in
terms of number of funded ATMP clinical trials [8]. This was due to
an important financial support from the ISCIII to non-commercial
clinical research and to the starting of the TerCel Network in the
more salutary period 20042010 [8]. More recent research in the
database clinicaltrials.gov [9] searching trials on “cell therapy” or
“stem cells” between 2011 and 2018 shows that Spain is the second
country in Europe in number of clinical trials (68 trials), just after
France (95 clinical trials).
Apart from considering all these achievements, with several suc-
cessful experiences as the development of Darvadstrocel that will be
discussed next, there are a number of pitfalls and lessons learned by
TerCel throughout this 15-year journey, especially when coordinating
all these academic research groups in an over-bureaucratized public
system from different regions with sometimes different research
structures. Probably the need of early collaboration to develop the pre-
clinical experiments and cooperation in the design of the clinical trials
is one of the most important learnings. We have faced scarce knowl-
edge in ATMP trials by Contract Research Organizations when we
started, and their cost remains excessive compared with the budget
generally obtained to perform clinical trials with ATMPs. Moreover,
although public-based Contract Research Organization platforms have
been developed in Spain (e.g., CAIBER and later SCReN platform), their
work is sometimes limited by scarce budget and personnel. For us, it
has been also essential to approach the regulatory agencies in a very
early stage of the development of the project. Training in regulatory
science in ATMPs is a clear “unmet need” in our scientific and clinical
environment. In this regard, we have to stress that the collaboration
with the SpanishMedicines Agency (AEMPS) has been crucial to obtain
many of TerCel’s achievements. In this regard, TerCel investigators
have established regular meetings with AEMPS representatives to dis-
cuss common problems and areas of interest, and AEMPS has been
extremely open to implement the rules to obtain good-quality ATMP
products, giving scientific and technical advice in clinical trial applica-
tion and being rigorous but constructive in the inspections of the GMP
facilities, among other interactions with the network.
TerCel and a Case of Successful Public-Private Collaboration in
Spain: Darvadstrocel
Darvadstrocel (named Cx601 during drug development, and now
commercially known as Alofisel) is the tenth ATMP approved in the EU
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geneic cells [10,11]. This product is based on adipose tissue derived
mesenchymal stromal cells (MSCs) and its labeled therapeutic indica-
tion is for the treatment of complex perianal fistulas in adult patients
with nonactive/mildly active luminal Crohn’s disease, when fistulas
have shown an inadequate response to at least one conventional or
biologic therapy [12]. Its efficacy was demonstrated in a randomized
phase 3 clinical trial, in which the primary endpoint was a strict com-
bined remission outcome at week 24 (i.e., clinical assessment of clo-
sure of all treated external openings that were draining at baseline,
and absence of collections >2 cm of the treated perianal fistulas con-
firmed using masked central magnetic resonance imaging) showed
that the experimental arm (Cx601) provided significantly better
results than placebo (50% versus 34%; P = 0.024), with no differences
in secondary effects (anal abscesses and proctalgia) [13]. These results
were further confirmed with a longer follow-up [14]. The interesting
issue with this product is that the initial idea started back in 2002 in
one of the TerCel groups in Madrid (located in the “La Paz” Hospital
and Autonomous University of Madrid [UAM]), led by Professor Dam-
ian García Olmo. In 2004 they established a fruitful collaboration with
the Spanish biotech company Cellerix, which sponsored the first clini-
cal trials with the product. In 2011, the Belgian company Tigenix
acquired Cellerix, but the cell production remained based in Tres Can-
tos (Madrid). Tigenix further developed the product until its approval
in March 2018 by the European Medicines Agency after the outcome
of the pivotal phase 3 trial ADMIRE-CD [3,14]. Takeda, one of the big-
gest pharmaceutical companies, with an increased interest in ATMP
products, will finally commercialize the drug in Europe and other mar-
kets. The model of collaborative work established between the “La
Paz” University Hospital, UAM, TerCel network research groups and
Tigenix has been the cornerstone for the development of Darvadstro-
cel. This is an example of how networking and collaborative
approaches can propel the transfer of ATMPs based on cell products
from academic research groups to patients through biotechnology or
big pharmaceutical companies.TerCel and Future Areas for Improvement
The Tigenix-La Paz-UAM-TerCel strategy has been a story of suc-
cess but additional approaches in the same way with other products
need to be promoted. TerCel currently holds 13 patents under exploi-
tation (of a total of 63 patents registered by TerCel groups) and more
collaboration with biotechnology companies is needed. In addition,
the development of large multicenter phase 3 trials within the net-
work should be increased. In this regard, in 2017 three TerCel part-
ners were included in a European multicenter phase 2b trial in
degenerative disc disease (RESPINE) [15], and in 2018, six phase 2
and 3 multicenter trials have obtained public funding and will be
completed in the next few years. These include the ARTROCELL trial
(a randomized phase 3 trial comparing intra-articular administration
of autologous versus allogeneic MSCs versus hyaluronic acid for knee
osteoarthrosis), the NOMA (No More Amputations) trial (another
phase 3 trial that compares different doses of MSCs in the treatment
of diabetic foot), the AGTPII trial (a phase 2 trial that evaluates the
effects of the adipose-derived graft transposition in myocardial post-
ischemic scars), the CaSeC-HF trial (a phase 2 study assessing the
safety and efficacy of intracoronary allogeneic cardiac stem cells in
ischemic chronic heart failure) and a phase 2 trial that explores the
role of intramuscular autologous mononuclear cells in amyotrophic
lateral sclerosis. Finally, for the sixth trial (CART19-BE-02), some Ter-
Cel groups have started to collaborate in new approaches to cover
academic immunotherapy trials with CAR technology [16]. This trial
will explore the role of ARI-001 (an academic CAR-T developed at the
Hospital Clinic in Barcelona) in patients with CD19+ relapsed or
refractory acute lymphoid leukemia.It is clear that with the GMP facilities network built, the collabora-
tive experience acquired and the partnerships established with some
biotechnological and pharmaceutical companies, the current situation
should foster the development of new academic-based cell products in
more applications. Because for some indications they may co-exist
with commercial ATMPs, it will be important to find clinical settings
and technological challenges where both strategies may become syn-
ergic and avoid competition.
Conclusion
In summary, the Institute of Health Carlos III approach to promote
cell therapy in the Spanish national health system through the TerCel
network has proven to be successful. It has provided a framework for
scientific interaction and for the promotion of translational research.
TerCel has demonstrated that these new therapies can be safely
translated to the patients, the feasibility of performing collaborative
clinical trials in this field and also the possibility of transferring new
products to the market.
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